Mario Tiribelli
Mario Tiribelli
Ricercatore In Ematologia
Verified email at
Cited by
Cited by
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ...
Clinical Cancer Research 12 (24), 7374-7379, 2006
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ...
Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
M Baccarani, D Cilloni, M Rondoni, E Ottaviani, F Messa, S Merante, ...
haematologica 92 (9), 1173-1179, 2007
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
P Secchiero, E Barbarotto, M Tiribelli, C Zerbinati, MG Di Iasio, A Gonelli, ...
Blood 107 (10), 4122-4129, 2006
Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine
CL Balduini, M Cattaneo, F Fabris, P Gresele, A Iolascon, FM Pulcinelli, ...
haematologica 88 (5), 582-592, 2003
The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype
D Damiani, M Tiribelli, E Calistri, A Geromin, A Chiarvesio, A Michelutti, ...
haematologica 91 (6), 825-828, 2006
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
G Gugliotta, F Castagnetti, F Palandri, M Breccia, T Intermesoli, A Capucci, ...
Blood, The Journal of the American Society of Hematology 117 (21), 5591-5599, 2011
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi, B Giannini, ...
Blood 103 (6), 2284-2290, 2004
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid …
A Candoni, M Tiribelli, E Toffoletti, D Cilloni, A Chiarvesio, A Michelutti, ...
European journal of haematology 82 (1), 61-68, 2009
Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies
A Candoni, R Mestroni, D Damiani, M Tiribelli, A Michelutti, F Silvestri, ...
European journal of haematology 75 (3), 227-233, 2005
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
F Efficace, M Baccarani, G Rosti, F Cottone, F Castagnetti, M Breccia, ...
British journal of cancer 107 (6), 904-909, 2012
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism
P Secchiero, E Melloni, MG Di Iasio, M Tiribelli, E Rimondi, F Corallini, ...
Blood, The Journal of the American Society of Hematology 113 (18), 4300-4308, 2009
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells
P Secchiero, C Zerbinati, M Grazia di Iasio, E Melloni, M Tiribelli, V Grill, ...
Current drug metabolism 8 (4), 395-403, 2007
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases
F Zaja, N Vianelli, A Sperotto, F Patriarca, M Tani, L Marin, M Tiribelli, ...
Leukemia & lymphoma 44 (11), 1951-1955, 2003
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome
F Palandri, I Iacobucci, F Castagnetti, N Testoni, A Poerio, M Amabile, ...
haematologica 93 (5), 770-774, 2008
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia
R Latagliata, M Breccia, C Fava, F Stagno, M Tiribelli, L Luciano, ...
Hematological oncology 31 (2), 103-109, 2013
Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells
P Secchiero, E Barbarotto, A Gonelli, M Tiribelli, C Zerbinati, C Celeghini, ...
The American journal of pathology 167 (6), 1599-1607, 2005
Differences among young adults, adults and elderly chronic myeloid leukemia patients
F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ...
Annals of Oncology 26 (1), 185-192, 2015
The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts
P Secchiero, C Zerbinati, E Melloni, D Milani, D Campioni, R Fadda, ...
Neoplasia 9 (10), 853-861, 2007
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α‐interferon
British journal of haematology 111 (2), 587-595, 2000
The system can't perform the operation now. Try again later.
Articles 1–20